What Are Host Cell Proteins in Biologics?

What You Need to Know

Host cell proteins (HCPs) are process-related impurities from the cells used to manufacture biologics.
They can affect drug efficacy, safety and stability.
Regulatory agencies like the FDA, EMA and MHRA require HCPs to be monitored and controlled.
Common detection methods include ELISA and LC-MS.
BioPharmaSpec offers expert support with orthogonal HCP-MS analysis and regulatory-aligned strategies.

Why Host Cell Proteins Matter

Whether you are preparing an IND submission, troubleshooting a stability issue, or scoping analytical services for a new biologic or therapeutic protein, understanding host cell proteins is key. These proteins may be present at low levels, but their impact can be significant. This blog explains what HCPs are, why they matter in drug development, and how BioPharmaSpec can help you detect and control them with confidence.

Two scientists wearing lab coats and gloves are using a digital tablet in a modern laboratory, conducting medical research with advanced equipment

What Are Host Cell Proteins?

Host cell proteins are residual proteins produced by the host organisms (e.g. CHO cells, E. coli, yeast) used during biopharmaceutical manufacturing. During the purification process, most HCPs are removed, but trace levels may remain in the final product.

These residual proteins are classified as process-related impurities and are considered critical quality attributes (CQAs) in regulatory submissions. Even in small quantities, host cell proteins can:

Trigger unwanted immune responses.
Compromise drug stability or activity.
Affect formulation shelf life.
Jeopardize regulatory approval.

Why Do Regulators Care About HCPs?

Agencies such as the FDA, EMA, and MHRA expect manufacturers to adhere to guidelines such as US 21CFR610.13, USP1132.1, EMA 3AB1a and ICH (Q6B) to demonstrate control over process impurities, including host cell proteins. Analytical data on HCP levels is typically required at the preclinical stages and during lot release in GMP manufacturing.

If host cell proteins are not properly identified or quantified, your submission may face delays or require additional testing. Regulators want to see that you have applied a risk-based strategy to monitor and minimize these impurities.

How Are Host Cell Proteins Detected?

There are two primary analytical methods used for host cell protein testing:

1. HCP ELISA (Enzyme-Linked Immunosorbent Assay)

Most widely used industry method.
Commercial kits are available for early-stage analysis.
Relies on polyclonal antibodies raised against the host cell line.
Provides an overall HCP level without detailed information on specific proteins.
Useful for routine batch release and process monitoring.
Can be limited by incomplete antibody coverage.

2. LC-MS (Mass Spectrometry-Based Methods)

Offers orthogonal analysis to complement ELISA.
Able to identify and quantify non-ELISA detectable or low-abundance individual HCPs.
Provides relative abundance of individual HCPs.
Absolute quantitation using synthetic analogs.
Enables protein-specific identification.
Requires a custom or commercial ion library for optimal performance.

At BioPharmaSpec, we regularly apply LC-MS techniques to help clients build robust, orthogonal host cell protein control strategies.

Scientist moved the vial of sample out from the tray autosampler of the Liquid Chromatography Mass Spectrometer LC/MS after the analysis was completed.

When Should Host Cell Protein Testing Be Conducted?

Host cell protein analysis should be performed at multiple stages of the development process to ensure impurity control, including:

Process development: to monitor purification efficiency.
Preclinical stages: to establish a baseline impurity profile.
Regulatory submissions (BLA/MAA): to demonstrate control.
GMP batch release testing: to ensure ongoing compliance.

We help clients interpret results, set appropriate specifications, and design a testing plan that aligns with their development timelines and filing goals.

Want To See How This Works in Practice?

Download our Technical Bulletin to learn how BioPharmaSpec uses LC-MS to support HCP profiling for a recombinant protein.

DOWNLOAD NOW

Common Challenges in Host Cell Protein Analysis

HCP monitoring is not always straightforward. Some of the most common issues include:

Poor antibody coverage in ELISA.
Lack of suitable HCP standards for new or unusual expression systems.
Data interpretation challenges when using multiple methods.
Time pressure to meet regulatory requirements.

Our team works closely with clients to anticipate these challenges early. Whether you are developing a new molecule or scaling an established production process, we offer consultative guidance, method selection and project scoping tailored to your goals.

Why Choose BioPharmaSpec for HCP Analysis?

BioPharmaSpec is a leading provider of regulatory-aligned analytical services for complex biological products. Here is how we can add value to your project:

Experience: Decades of hands-on work with recombinant proteins including monoclonal antibodies, both biosimilars and novel constructs.
Expertise: PhD-level scientists with a deep understanding of mass spectrometry.
Orthogonal Approaches: Integrated workflows for optimum LC-MS/MS HCP profiling methods.
Regulatory Familiarity: Our analytical strategies provide data which conform to the requirements of international guidelines including ICH Q6B.

Whether you are in the planning stages of your project or are facing a regulatory deadline and need help fast , we can help move your project forward with confidence and clarity.

Build a Confident HCP Strategy

Work with expert scientists to detect, quantify, and control host cell proteins at every stage of development.

EXPLORE HCP SERVICES

Frequently Asked Questions

Where do host cell proteins come from?

Host cell proteins (HCPs) are generated by the host organisms, such as Chinese Hamster Ovary Cells (CHO) or E. coli, used to manufacture biopharmaceutical products. These cells are engineered to produce therapeutic proteins, including monoclonal antibodies and other biologics, but they also produce their own native proteins. Some of these residual proteins can persist through purification and end up in the final product as process-related protein impurities.

Because each host cell line produces a unique protein profile, understanding the source and nature of host cell proteins is essential during process development. Early HCP analysis helps developers identify potential impurities, optimize purification strategies, and ensure that the final product meets regulatory expectations for safety and quality.

What are the implications of HCPs for downstream process development?

Host cell proteins can significantly influence downstream processing by affecting the efficiency of purification steps and the overall consistency of a biopharmaceutical product. If HCPs are not adequately cleared early in development, they may accumulate or become more difficult to remove later, increasing the risk of batch failure or regulatory scrutiny. Early HCP analysis helps inform purification strategy design, set relevant acceptance criteria, and reduce rework in later stages.

Do I need to use both ELISA and LC-MS?

What if my expression system is unusual?

How soon can testing start?

Ready to Take the Next Step?

Speak directly with one of our scientists to scope your project, discuss your testing goals, and receive a customised proposal.

What Are Host Cell Proteins in Biologics Development?